New Copaxone® data reported from AAN demonstrate clinical benefits of switching MS patients to Copaxone®.

April 12, 2011

Additional study data show significant improvement of cognition and improved quality of life measures following treatment with Copaxone^®.

These data will be presented on Wednesday, April 13 (Coptimize) and Thursday, April 14 (QualiCop). See abstracts embedded below.

·         Results from the Coptimize Study demonstrated that patients who switched to Copaxone^® from other approved injectable and infused disease modifying therapies experienced a significant reduction of 65 percent (p<0.0001; signed rank test) in annualized relapse rate (ARR).

·         Switching to Copaxone^® treatment also halted the progression of disability of patients in the trial as measured by expanded disability status scale (EDSS) scores.

·         Findings from the QualiCop Study revealed that patients who were either treatment naïve or previously-treated, showed a robust improvement in cognitive function, with 70 percent of patients (n=460) treated with Copaxone^® experiencing an improvement or stabilization in measures of cognition after 12 months of treatment.

·         Additionally, patients on Copaxone^® experienced improved overall multiple sclerosis functional composite (MSFC) scores; the MSFC measures leg function/ambulation, arm/hand function and cognitive function.

·         No disease progression was observed among patients over 12 months of treatment in the QualiCop Study.

.